Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its external Safety Review Committee recommended proceeding to the second cohort of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE